SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical or the Company) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical or the Company) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical or the Company) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical or the Company) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost...
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (Journey Medical or the Company), a commercial-stage pharmaceutical company that primarily...
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily...
Journey Medical to Announce Year End 2023 Financial Results on March 21, 2024
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference